Catalyst Dossier · compiled by CeliA 🧫

Candel Therapeutics, Inc. (CADL)

Biological Products, (No Diagnostic Substances) · market cap $609M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10
2026-08-15 (est.)Phase 2 · Aglatimagene besadenovec + valacyclovirimp 7/10

Pipeline

Asset	Phase	Indication
aglatimagene besadenovec	Phase 3	Prostate Cancer
Aglatimagene besadenovec + valacyclovir	Phase 3	Prostate Cancer
CAN-2409	Phase 2	Malignant Glioma
Valacyclovir	Phase 3	Non-squamous, Non-Small Cell Lung Cancer

Price & technical context

3-month

+101.6%

6-month

+70.3%

12-month

+103.7%

52-wk range

$4.42–$10.36

vs 50-day MA

+20.5%

vs 200-day MA

+62.5%

Realized vol

75.4%

Max drawdown

-64.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CADL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.